Lipanthylnano (Fenofibrate (Nanonised))

Fenofibrate is used to manage lipid disorders by reducing elevated cholesterol and triglyceride levels, thereby supporting cardiovascular health.

• Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol concentrations.
• Hypertriglyceridemia: reduces high triglyceride levels in the bloodstream.
• Mixed dyslipidemia: improves overall lipid profile by decreasing triglycerides and LDL‑cholesterol while modestly increasing HDL‑cholesterol.
• Cardiovascular risk reduction: contributes to lowering the risk of atherosclerotic events when combined with diet and lifestyle measures.

• Fenofibrate activates peroxisome proliferator‑activated receptor alpha (PPARα) in hepatic cells, leading to increased transcription of genes involved in fatty‑acid β‑oxidation and lipoprotein metabolism. This enhances catabolism of triglyceride‑rich lipoproteins, reduces hepatic secretion of very‑low‑density lipoprotein, and raises clearance of low‑density lipoprotein particles, resulting in lowered plasma triglycerides and cholesterol.

Fenofibrate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
• Elevated liver enzymes: transient increase in ALT or AST.
• Muscle pain: mild myalgia without weakness.
• Headache: occasional tension‑type headache.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with possible renal impairment.
• Hepatotoxicity: significant elevation of liver transaminases or jaundice.
• Severe hypersensitivity: rash, angioedema or anaphylactic reactions.

Before initiating Fenofibrate therapy, several safety considerations should be evaluated.

• Renal function: assess creatinine clearance, especially in patients with existing kidney disease.
• Hepatic status: avoid use in active liver disease or unexplained persistent elevations of transaminases.
• Muscle disorders: evaluate risk of myopathy, particularly when combined with statins.
• Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
• Drug interactions: review concomitant medications that may increase risk of myopathy or affect fenofibrate levels.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Fenofibrate can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Statins (especially high‑dose simvastatin): increased risk of rhabdomyolysis; avoid combination or use the lowest statin dose.
• Cyclosporine: may raise fenofibrate plasma concentrations, enhancing toxicity.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin): fenofibrate may potentiate anticoagulant effect; monitor INR.
• Bile‑acid sequestrants (cholestyramine): can reduce fenofibrate absorption; separate dosing by at least 1 hour.
• Oral hypoglycemics: may enhance glucose‑lowering effect; monitor blood sugar.